Inception IBD, Inc. Overview
Pro stress-test →Inception IBD is a San Diego-based private biotech company focused on discovering and developing first-in-class small molecule therapeutics for inflammatory bowel disease (IBD). Founded in 2014 as a spinout from Inception Sciences, the company translates academic discoveries into novel drug candidates targeting Crohn's disease and ulcerative colitis.
Strategic Profile
Pro stress-test →Operating within Inception Sciences' build-to-buy model partnership with Versant Ventures, Inception IBD benefits from access to integrated chemistry, biology, and DMPK capabilities. The company has secured strategic backing from major pharmaceutical players, including a notable collaboration with Celgene (announced December 2015) to advance IBD therapeutics, positioning it as a disciplined discovery player in the specialty pharma space.
Competitive Landscape
Pro stress-test →Inception IBD competes in the IBD therapeutics space against established players like Celgene (now part of Bristol Myers Squibb), AbbVie (Rinvoq, Skyrizi), Janssen (Stelara), and smaller biotech firms. The market is crowded with both TNF inhibitors and newer JAK inhibitors, but small molecule innovation opportunities remain, particularly for patients with inadequate responses to current therapies. Inception's partnership with Celgene positions it favorably within the competitive landscape.
Industry Context
Inception IBD, Inc. operates in Inflammatory Bowel Disease Therapeutics.
Key facts
Founded: 2014 · Headquarters: San Diego, California · Employees: Unknown · Revenue: N/A · Market cap: N/A